Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Inozyme Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
INZY
Nasdaq
8731
https://www.inozyme.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Inozyme Pharma Inc
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
- Apr 8th, 2024 10:30 am
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 5th, 2024 10:00 pm
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
- Apr 2nd, 2024 12:30 pm
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
- Mar 26th, 2024 12:30 pm
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
- Mar 12th, 2024 12:30 pm
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
- Feb 26th, 2024 1:30 pm
Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)
- Dec 21st, 2023 1:10 pm
Inozyme Pharma to Participate in Upcoming Investor Conferences
- Nov 9th, 2023 1:30 pm
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
- Nov 7th, 2023 1:30 pm
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
- Oct 26th, 2023 12:30 pm
10 Stocks With Huge Catalysts on the Way
- Oct 14th, 2023 4:07 pm
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
- Oct 10th, 2023 4:00 pm
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
- Oct 10th, 2023 12:30 pm
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
- Oct 6th, 2023 12:30 pm
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
- Sep 26th, 2023 11:30 am
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
- Sep 20th, 2023 12:30 pm
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 12:30 pm
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
- Aug 8th, 2023 12:30 pm
Insiders Pour Millions Into These 2 Stocks Under $10 — Here’s Why Wall Street Thinks They Could Double (or More)
- Aug 7th, 2023 2:50 pm
Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock
- Aug 1st, 2023 8:01 pm
Scroll